FC05
A SARS-CoV-2-neutralizing antibody.
General information
FC05 is a human monoclonal antibody targeting SARS-CoV-2 Spike NTD, identified in peripheral blood mononuclear cells from COVID-19 convalescent patients using phage display technique (Zhang et al., 2020). FC05 binding affinity for Spike protein trimers of B.1.1.7 and B.1.351 is significantly reduced. For a standard version of Spike protein, the antibody displayed cooperative binding with antibodies HB27, P17, and H014 (Sun et al., 2021; Wang et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Structure-based development of human antibody cocktails against SARS-CoV-2
Spike protein Biophysical assay Animal model In vitro Antibody |
in vitro biophysical assay; 293T cells (cell-to-cell fusion assay); Vero cells; Huh7 cells; hACE2-mice; BALB/c mice | 20.51 | The antibody binds to the SARS-CoV-2 spike protein synergistically with H014, P17, or HB27. |
Dec/01/2020 |
|
Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms
Spike protein Cryo-EM Biophysical assay In vitro Antibody |
in vitro biophysical assay; cryo-EM | 20.51 | FC05 affinity for Spike protein trimers of B.1.1.7 and B.1.351 was significantly reduced. For a standard version of Spike protein, the antibody displayed cooperative binding with antibodies HB27, P17, and H014. |
Mar/29/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2.
|
Mar/27/2021 |
